Mnemo Therapeutics
Noémie Gaudin has a long history of research experience. In 2013, they worked as a Research Assistant at the Centre de recherche du CHU de Quèbec-Université Laval, where they investigated the recruitment of the Sam68 protein to the spreading initiation center. In 2014, they worked as a Research Assistant at the University College Cork, where they evaluated the efficacy of a nisin derivative versus the wild type against Staphylococcus pseudintermedius. In 2015, they worked as a Research Assistant at the Candiolo Cancer Institute IRCCS, where they investigated the effect of bisphosphonates on the immune function in cervical carcinoma of HPV transgenic mice. In 2016, they worked as a Research Assistant at the Institut Jacques Monod, where they were in charge of the functional characterization of the hVFL1 protein at the centrosome and at the primary cilium. Noémie also worked as a Researcher Phd Candidate at the same institute, during which they investigated the molecular mechanisms associated with centriole rotational polarity in animal cells. Finally, they are currently working as a Scientist in Cell Biology and Biobanking at Mnemo Therapeutics, starting in 2022.
Noémie Gaudin's education history includes a Bachelor of Science degree in Molecular Biology, Cell Biology and Physiology from Université Paris-Est Créteil (UPEC) from 2014 to 2015, a DUT Génie Biologique majoring in biological and biochemical analyzes from IUT Créteil-Vitry, UPEC, University Paris 12 from 2011 to 2013, an Applied Biosciences and Biotechnology (BSc Degree) year 3 from Munster Technological University from 2013 to 2014, and a Certificate of animal testing level 2 from IUT Créteil-Vitry, UPEC, University Paris 12 from 2012 to 2013. Noémie also completed a Master in Biologie cellulaire et moléculaire from Sorbonne Université from 2015 to 2017, and a Thèse de doctorat in Biologie Cellulaire from Université Paris Cité from 2017 to 2021. Additionally, they earned a Certificat de pédagogie Universitaire Doctens from Université Paris Cité in 2017.
This person is not in any offices
Mnemo Therapeutics
1 followers
Mnemo Therapeutics is a biotechnology company focused on developing powerful cell therapies that create accessible cures for solid tumors and blood cancers. Its EnfiniT platform, a groundbreaking drug discovery engine, leverages a new class of antigens with greater tumor specificity and a suite of technologies to significantly improve T cell memory, persistence, and sensitivity. The result is dramatic improvement in the body’s immune response to overcome disease. Mnemo is built by a transatlantic team of scientists and biotech leaders united in their mission to create the most powerful immune therapies to deliver accessible cures for all patients in need.